UK health tech company Medopad has announced its entry into the United States market with the acquisition of Sherbit, a Silicon Valley artificial intelligence start-up.
Medopad’s acquisition of Sherbit marks a significant milestone in its US expansion strategy. Sherbit collaborates with some of the largest healthcare systems in the United States to enhance chronic disease patient care. Medopad, known for connecting patients with healthcare professionals to analyse data and detect life-threatening medical conditions, already has collaborations with prominent UK institutions such as Royal Free London, Guy’s and St Thomas’, Bart’s, and Chelsea & Westminster.
In addition to its UK partnerships, Medopad is involved in projects across China, Germany, and Singapore. Recognised by KPMG as a potential $1 billion HealthTech business, Medopad aims to extend the lives of a billion people worldwide. CEO and founder Dan Vahdat articulated the company’s vision: “At Medopad we want to create a world where people can live longer. We are working with some of the biggest companies in the world to improve the way doctors care for their patients by monitoring them at home and spotting any complications before they arise.”
The acquisition of Sherbit is the first step in Medopad’s strategic US expansion. Sherbit boasts a proven track record with renowned US healthcare organisations, including the Mayo Clinic, Tufts Medical Center, and Jefferson Health. Vahdat emphasised the broader implications of the acquisition: “Through this acquisition, Medopad will provide its technology to support solutions across different disease areas from rare diseases to chronic conditions.”
Sherbit CEO Alex Senemar echoed this sentiment, highlighting the shared vision between the two companies: “Sherbit and Medopad have the same vision to help people be healthier and live longer. We’re excited to leverage Medopad’s technology, clinical, and predictive analytics capabilities to expand what’s possible for our customers.”
The acquisition of Sherbit signals Medopad’s commitment to expanding its influence and capabilities in the healthcare sector, particularly within the United States. This move is set to enhance its technological offerings and extend its global reach.